Alterome Therapeutics, Inc., a next-generation precision oncology company pioneering the development of alteration-specific targeted therapies for the treatment of cancer, announced the appointment of Andrew S. Chi, M.D., Ph.D., as its Chief Medical Officer.
“We are excited to welcome Andrew to Alterome during this important phase as we advance our first two programs into the clinic next year,” said Eric Murphy, Ph.D., co-founder, CEO and CSO of Alterome Therapeutics. “Andrew is a talented physician-scientist who brings considerable expertise across all stages of oncology drug development spanning clinical and translational research through global Phase III studies. His appointment strengthens our leadership team as we advance Alterome’s pipeline of next-generation precision oncology programs.”
“I’m excited to join Alterome’s mission to discover alteration-specific targeted therapies that improve patient outcomes and inspire hope for individuals affected by cancer,” said. Dr. Chi. “I look forward to working alongside the team of accomplished oncology experts as Alterome advances its first two programs targeting high-value oncogenic drivers into the clinic next year.”
Also Read: Introducing NeoMab: GemPharmatech’s Innovative Antibody Gene Humanized Mouse Model
Dr. Chi joins Alterome with more than two decades of experience in oncology research and drug development. Previously, he served as Vice President of Clinical Development at Bright Peak Therapeutics, and before that, he was Executive Medical Director at Mirati Therapeutics where he led the clinical development of adagrasib (KRAS G12C inhibitor KRAZATI®) across multiple disease areas, successfully achieving FDA Breakthrough Therapy designation in lung cancer. Before that, he was Senior Director, Clinical Development, at Neon Therapeutics, which was acquired by BioNTech. Prior to working in biotech, he had a successful academic career, serving as Chief of Neuro-oncology and Co-Director of the Brain Tumor Center at New York University and founder and director of the Translational Neuro-Oncology Laboratory at Massachusetts General Hospital.
As a principal investigator he authored over 90 peer-reviewed publications and multiple patents and identified multiple novel therapeutic targets in glioma. A board-certified neuro-oncologist and neurologist, he earned his B.A. in biochemistry and molecular biology from Boston University and completed a joint M.D./Ph.D. program at Chicago Medical School/Rosalind Franklin University of Medicine and Science. He then completed Neurology residency and Neuro-oncology fellowship at the Harvard Medical School programs at Massachusetts General Hospital, Brigham and Women’s Hospital and Dana-Farber Cancer Institute, followed by postdoctoral training in cancer genomics and epigenomics at the Broad Institute of MIT and Harvard. In addition, he has served as a Senior Editor for Clinical Cancer Research since 2017.
SOURCE: Businesswire